pharma · Tuberculosis · Meningococcal Meningitis
CanSino Biologics drug portfolio — 9 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Portfolio lens on 9 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
CanSino Biologics drug portfolio — 9 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Antiinfectives for systemic use (J07) compound in CanSino Biologics's portfolio.
Development asset linked to CanSino Biologics in public FDA and regional records.
Development asset linked to CanSino Biologics in public FDA and regional records.
Development asset linked to CanSino Biologics in public FDA and regional records.
Development asset linked to CanSino Biologics in public FDA and regional records.
Various (V04) compound in CanSino Biologics's portfolio.
Development asset linked to CanSino Biologics in public FDA and regional records.
US regulatory status: approved.
Development asset linked to CanSino Biologics in public FDA and regional records.